Compounds > db 820
Page last updated: 2024-12-11

db 820

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID9817976
CHEMBL ID145251
SCHEMBL ID5490613
MeSH IDM0490033

Synonyms (4)

Synonym
CHEMBL145251
db820
6-[5-(4-carbamimidoylphenyl)-2-furyl]pyridine-3-carboxamidine
SCHEMBL5490613

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Compound 6a produced cures at an oral dosage of 5 mg/kg."( Synthesis and antiprotozoal activity of aza-analogues of furamidine.
Boykin, DW; Brun, R; Easterbrook, JD; Ismail, MA; Tanious, FA; Wilson, WD, 2003)		0.32
" The amidoxime and N-methoxyamidine of 5a were the only produgs to provide cures (1/4 cures) in the same mouse model on oral dosage at 4x25mg/kg."( Synthesis and antiprotozoal activity of 2,5-bis[amidinoaryl]thiazoles.
Boykin, DW; Branowska, D; Brun, R; Farahat, AA; Kumar, A; Liu, Y; Wenzler, T; Wilson, WD, 2010)		0.36
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (69)

Assay IDTitleYearJournalArticle
AID779106Cytotoxicity against rat L6 cells assessed as cell viability after 70 hrs by Alamar blue assay2013Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21
Synthesis and antiprotozoal activity of dicationic 2,6-diphenylpyrazines and aza-analogues.
AID124386No. of mice that survived T.b. rhodesiense infection and are parasite free for 60 days was determined at dose of 20 mg/kg by i.p. administration; 4 animals tested2003Journal of medicinal chemistry, Oct-23, Volume: 46, Issue:22
Synthesis and antiprotozoal activity of aza-analogues of furamidine.
AID454676Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB900 infected in NMRI mouse assessed as survival at 20 mg/kg, ip2009Bioorganic & medicinal chemistry, Sep-15, Volume: 17, Issue:18
Synthesis and activity of azaterphenyl diamidines against Trypanosoma brucei rhodesiense and Plasmodium falciparum.
AID454679Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB900 infected in NMRI mouse assessed as survival days at 5 mg/kg, ip2009Bioorganic & medicinal chemistry, Sep-15, Volume: 17, Issue:18
Synthesis and activity of azaterphenyl diamidines against Trypanosoma brucei rhodesiense and Plasmodium falciparum.
AID481848Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB900 in infected mouse model assessed as host survival time at 5 mg/kg, ip for 4 days2010Bioorganic & medicinal chemistry, May-15, Volume: 18, Issue:10
Synthesis and antiprotozoal activity of 2,5-bis[amidinoaryl]thiazoles.
AID565602Antimicrobial activity against Trypanosoma evansi STIB 806K infected in NMRI mouse assessed as host survival days at 0.5 mg/kg, ip administered 3 to 6 days after infection for 4 consecutive days2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
In vivo investigations of selected diamidine compounds against Trypanosoma evansi using a mouse model.
AID454674Selectivity ratio of IC50 for Trypanosoma brucei rhodesiense STIB900 to IC50 for Plasmodium falciparum K12009Bioorganic & medicinal chemistry, Sep-15, Volume: 17, Issue:18
Synthesis and activity of azaterphenyl diamidines against Trypanosoma brucei rhodesiense and Plasmodium falciparum.
AID340903Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB900 after 72 hrs2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Diphenyl furans and aza analogs: effects of structural modification on in vitro activity, DNA binding, and accumulation and distribution in trypanosomes.
AID562514Antitrypanosomal activity against Trypanosoma brucei brucei GVR35 infected in NMRI mouse CNS model assessed as cure from infection at 20 mg/kg, ip for 5 days2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
New treatment option for second-stage African sleeping sickness: in vitro and in vivo efficacy of aza analogs of DB289.
AID562488Antitrypanosomal activity against Trypanosoma brucei gambiense ITMAP141267 by Alamar blue assay2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
New treatment option for second-stage African sleeping sickness: in vitro and in vivo efficacy of aza analogs of DB289.
AID562501Antitrypanosomal activity against wild-type Trypanosoma brucei rhodesiense STIB900 infected in NMRI mouse assessed as cure from infection at 0.5 mg/kg, ip for 4 days2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
New treatment option for second-stage African sleeping sickness: in vitro and in vivo efficacy of aza analogs of DB289.
AID562502Antitrypanosomal activity against wild-type Trypanosoma brucei rhodesiense STIB900 infected in NMRI mouse assessed as survival of mouse at 20 mg/kg, ip for 4 days2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
New treatment option for second-stage African sleeping sickness: in vitro and in vivo efficacy of aza analogs of DB289.
AID454672Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB9002009Bioorganic & medicinal chemistry, Sep-15, Volume: 17, Issue:18
Synthesis and activity of azaterphenyl diamidines against Trypanosoma brucei rhodesiense and Plasmodium falciparum.
AID562496Ratio of IC50 for Trypanosoma brucei gambiense STIB930 to IC50 for wild-type Trypanosoma brucei rhodesiense STIB9042009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
New treatment option for second-stage African sleeping sickness: in vitro and in vivo efficacy of aza analogs of DB289.
AID565603Antimicrobial activity against Trypanosoma evansi STIB 806K infected in NMRI mouse assessed as host survival days at 0.25 mg/kg, ip administered 3 to 6 days after infection for 4 consecutive days2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
In vivo investigations of selected diamidine compounds against Trypanosoma evansi using a mouse model.
AID481843Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB9002010Bioorganic & medicinal chemistry, May-15, Volume: 18, Issue:10
Synthesis and antiprotozoal activity of 2,5-bis[amidinoaryl]thiazoles.
AID340902Antitrypanosomal activity against Trypanosoma brucei brucei S427 after 72 hrs2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Diphenyl furans and aza analogs: effects of structural modification on in vitro activity, DNA binding, and accumulation and distribution in trypanosomes.
AID454673Antiplasmodial activity against Plasmodium falciparum K12009Bioorganic & medicinal chemistry, Sep-15, Volume: 17, Issue:18
Synthesis and activity of azaterphenyl diamidines against Trypanosoma brucei rhodesiense and Plasmodium falciparum.
AID123992In vivo average survival rate of mouse infected by T.b. rhodesiense was determined for a period of 60 days at dose of 20 mg/kg by i.p. administration2003Journal of medicinal chemistry, Oct-23, Volume: 46, Issue:22
Synthesis and antiprotozoal activity of aza-analogues of furamidine.
AID779107Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB900 assessed as parasite growth inhibition after 70 hrs by Alamar blue assay2013Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21
Synthesis and antiprotozoal activity of dicationic 2,6-diphenylpyrazines and aza-analogues.
AID208055In vitro inhibitory activity against T. b. rhodesiense2003Journal of medicinal chemistry, Oct-23, Volume: 46, Issue:22
Synthesis and antiprotozoal activity of aza-analogues of furamidine.
AID481845Cytotoxicity against rat L6 cells2010Bioorganic & medicinal chemistry, May-15, Volume: 18, Issue:10
Synthesis and antiprotozoal activity of 2,5-bis[amidinoaryl]thiazoles.
AID562487Antitrypanosomal activity against Trypanosoma brucei gambiense K03048 by Alamar blue assay2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
New treatment option for second-stage African sleeping sickness: in vitro and in vivo efficacy of aza analogs of DB289.
AID562505Antitrypanosomal activity against wild-type Trypanosoma brucei rhodesiense STIB900 infected in NMRI mouse assessed as survival of mouse at 2.5 mg/kg, ip for 4 days2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
New treatment option for second-stage African sleeping sickness: in vitro and in vivo efficacy of aza analogs of DB289.
AID562491Antitrypanosomal activity against Trypanosoma brucei brucei AT1KO by Alamar blue assay2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
New treatment option for second-stage African sleeping sickness: in vitro and in vivo efficacy of aza analogs of DB289.
AID322579Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB900 infected mouse model assessed as survival at 5 mg/kg, ip after 4 days2008Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2
Synthesis and antiprotozoal activity of novel bis-benzamidino imidazo[1,2-a]pyridines and 5,6,7,8-tetrahydro-imidazo[1,2-a]pyridines.
AID565607Antimicrobial activity against Trypanosoma evansi STIB 806K infected in NMRI mouse assessed as complete cure from microbial infection at 0.5 mg/kg, ip administered 3 to 6 days after infection for 4 consecutive days2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
In vivo investigations of selected diamidine compounds against Trypanosoma evansi using a mouse model.
AID54997In vitro binding affinity towards calf thymus (CT DNA)2003Journal of medicinal chemistry, Oct-23, Volume: 46, Issue:22
Synthesis and antiprotozoal activity of aza-analogues of furamidine.
AID562489Antitrypanosomal activity against Trypanosoma brucei gambiense STIB930 by Alamar blue assay2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
New treatment option for second-stage African sleeping sickness: in vitro and in vivo efficacy of aza analogs of DB289.
AID562518Antitrypanosomal activity against Trypanosoma brucei brucei GVR35 infected in NMRI mouse CNS model assessed as survival of mouse at 20 mg/kg, ip for 10 days2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
New treatment option for second-stage African sleeping sickness: in vitro and in vivo efficacy of aza analogs of DB289.
AID562506Antitrypanosomal activity against wild-type Trypanosoma brucei rhodesiense STIB900 infected in NMRI mouse assessed as survival of mouse at 0.5 mg/kg, ip for 4 days2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
New treatment option for second-stage African sleeping sickness: in vitro and in vivo efficacy of aza analogs of DB289.
AID562499Antitrypanosomal activity against wild-type Trypanosoma brucei rhodesiense STIB900 infected in NMRI mouse assessed as cure from infection at 20 mg/kg, ip for 4 days2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
New treatment option for second-stage African sleeping sickness: in vitro and in vivo efficacy of aza analogs of DB289.
AID340906Drug level in Trypanosoma brucei brucei S427 at 7.5 uM after 8 hrs2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Diphenyl furans and aza analogs: effects of structural modification on in vitro activity, DNA binding, and accumulation and distribution in trypanosomes.
AID454678Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB900 infected in NMRI mouse assessed as survival days at 20 mg/kg, ip2009Bioorganic & medicinal chemistry, Sep-15, Volume: 17, Issue:18
Synthesis and activity of azaterphenyl diamidines against Trypanosoma brucei rhodesiense and Plasmodium falciparum.
AID779108Binding affinity to poly(dA-dT)2 DNA (unknown origin) assessed as change in melting temperature by spectrophotometric analysis2013Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21
Synthesis and antiprotozoal activity of dicationic 2,6-diphenylpyrazines and aza-analogues.
AID562494Ratio of IC50 for Trypanosoma brucei gambiense K03048 to IC50 for wild-type Trypanosoma brucei rhodesiense STIB9022009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
New treatment option for second-stage African sleeping sickness: in vitro and in vivo efficacy of aza analogs of DB289.
AID151198In vitro inhibitory activity against Plasmodium falciparum2003Journal of medicinal chemistry, Oct-23, Volume: 46, Issue:22
Synthesis and antiprotozoal activity of aza-analogues of furamidine.
AID562517Antitrypanosomal activity against Trypanosoma brucei brucei GVR35 infected in NMRI mouse CNS model assessed as survival of mouse at 20 mg/kg, ip for 5 days2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
New treatment option for second-stage African sleeping sickness: in vitro and in vivo efficacy of aza analogs of DB289.
AID779105Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB900 infected in NMRI mouse assessed as cured animal at 20 mg/kg, ip administered on day 3 post infection for 4 days measured up to 60 days2013Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21
Synthesis and antiprotozoal activity of dicationic 2,6-diphenylpyrazines and aza-analogues.
AID162419In vitro binding affinity towards Poly (dA-dT)22003Journal of medicinal chemistry, Oct-23, Volume: 46, Issue:22
Synthesis and antiprotozoal activity of aza-analogues of furamidine.
AID481842Binding affinity to poly(dA.dT) assessed as change in melting temperature by spectrophotometry2010Bioorganic & medicinal chemistry, May-15, Volume: 18, Issue:10
Synthesis and antiprotozoal activity of 2,5-bis[amidinoaryl]thiazoles.
AID454680Binding affinity to DNA assessed as change in melting temperature2009Bioorganic & medicinal chemistry, Sep-15, Volume: 17, Issue:18
Synthesis and activity of azaterphenyl diamidines against Trypanosoma brucei rhodesiense and Plasmodium falciparum.
AID562503Antitrypanosomal activity against wild-type Trypanosoma brucei rhodesiense STIB900 infected in NMRI mouse assessed as survival of mouse at 10 mg/kg, ip for 4 days2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
New treatment option for second-stage African sleeping sickness: in vitro and in vivo efficacy of aza analogs of DB289.
AID481844Antiplasmodial activity against Plasmodium falciparum K12010Bioorganic & medicinal chemistry, May-15, Volume: 18, Issue:10
Synthesis and antiprotozoal activity of 2,5-bis[amidinoaryl]thiazoles.
AID562504Antitrypanosomal activity against wild-type Trypanosoma brucei rhodesiense STIB900 infected in NMRI mouse assessed as survival of mouse at 5 mg/kg, ip for 4 days2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
New treatment option for second-stage African sleeping sickness: in vitro and in vivo efficacy of aza analogs of DB289.
AID340905Binding affinity at d(CGCGAATTCGCG) synthetic oligomer duplex assessed as increase in melting temperature2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Diphenyl furans and aza analogs: effects of structural modification on in vitro activity, DNA binding, and accumulation and distribution in trypanosomes.
AID562500Antitrypanosomal activity against wild-type Trypanosoma brucei rhodesiense STIB900 infected in NMRI mouse assessed as cure from infection at 10 mg/kg, ip for 4 days2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
New treatment option for second-stage African sleeping sickness: in vitro and in vivo efficacy of aza analogs of DB289.
AID340909Binding affinity to Clostridium perfringens genomic DNA assessed as decrease in fluorescence intensity at 1 uM by fluorescence spectral method relative to control2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Diphenyl furans and aza analogs: effects of structural modification on in vitro activity, DNA binding, and accumulation and distribution in trypanosomes.
AID565597Antimicrobial activity against Trypanosoma evansi STIB 806K infected in NMRI mouse assessed as host survival days at 0.125 mg/kg, ip administered 3 to 6 days after infection for 4 consecutive days2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
In vivo investigations of selected diamidine compounds against Trypanosoma evansi using a mouse model.
AID322575Binding affinity to poly(dA-dT) DNA2008Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2
Synthesis and antiprotozoal activity of novel bis-benzamidino imidazo[1,2-a]pyridines and 5,6,7,8-tetrahydro-imidazo[1,2-a]pyridines.
AID562484Antitrypanosomal activity against wild-type Trypanosoma brucei rhodesiense STIB900 by Alamar blue assay2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
New treatment option for second-stage African sleeping sickness: in vitro and in vivo efficacy of aza analogs of DB289.
AID562495Ratio of IC50 for Trypanosoma brucei gambiense ITMAP141267 to IC50 for wild-type Trypanosoma brucei rhodesiense STIB9032009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
New treatment option for second-stage African sleeping sickness: in vitro and in vivo efficacy of aza analogs of DB289.
AID562492Ratio of IC50 for pentamidine-resistant Trypanosoma brucei rhodesiense STIB900 to IC50 for wild-type Trypanosoma brucei rhodesiense STIB9002009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
New treatment option for second-stage African sleeping sickness: in vitro and in vivo efficacy of aza analogs of DB289.
AID779103Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB900 infected in NMRI mouse assessed as mouse survival at 20 mg/kg, ip administered on day 3 post infection for 4 days measured up to 60 days2013Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21
Synthesis and antiprotozoal activity of dicationic 2,6-diphenylpyrazines and aza-analogues.
AID562490Antitrypanosomal activity against Trypanosoma brucei brucei BS221 by Alamar blue assay2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
New treatment option for second-stage African sleeping sickness: in vitro and in vivo efficacy of aza analogs of DB289.
AID779102Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB900 infected in NMRI mouse assessed as mouse survival at 5 mg/kg, ip administered on day 3 post infection for 4 days measured up to 60 days2013Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21
Synthesis and antiprotozoal activity of dicationic 2,6-diphenylpyrazines and aza-analogues.
AID779109Antiplasmodial activity against Plasmodium falciparum K1 assessed as [3H]-hypoxanthine incorporation after 48 hrs by liquid scintillation counting analysis2013Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21
Synthesis and antiprotozoal activity of dicationic 2,6-diphenylpyrazines and aza-analogues.
AID562498Ratio of IC50 for Trypanosoma brucei gambiense K03048 to IC50 for Trypanosoma brucei gambiense STIB9302009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
New treatment option for second-stage African sleeping sickness: in vitro and in vivo efficacy of aza analogs of DB289.
AID322578Cytotoxicity against rat L6 cells2008Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2
Synthesis and antiprotozoal activity of novel bis-benzamidino imidazo[1,2-a]pyridines and 5,6,7,8-tetrahydro-imidazo[1,2-a]pyridines.
AID322576Antiprotozoan activity against Trypanosoma brucei rhodesiense STIB9002008Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2
Synthesis and antiprotozoal activity of novel bis-benzamidino imidazo[1,2-a]pyridines and 5,6,7,8-tetrahydro-imidazo[1,2-a]pyridines.
AID562493Ratio of IC50 for melasoprol-resistant Trypanosoma brucei rhodesiense STIB900 to IC50 for wild-type Trypanosoma brucei rhodesiense STIB9012009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
New treatment option for second-stage African sleeping sickness: in vitro and in vivo efficacy of aza analogs of DB289.
AID562497Ratio of IC50 for Trypanosoma brucei brucei AT1KO to IC50 for Trypanosoma brucei brucei BS2212009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
New treatment option for second-stage African sleeping sickness: in vitro and in vivo efficacy of aza analogs of DB289.
AID562486Antitrypanosomal activity against melasoprol-resistant Trypanosoma brucei rhodesiense STIB900 by Alamar blue assay2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
New treatment option for second-stage African sleeping sickness: in vitro and in vivo efficacy of aza analogs of DB289.
AID562485Antitrypanosomal activity against pentamidine-resistant Trypanosoma brucei rhodesiense STIB900 by Alamar blue assay2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
New treatment option for second-stage African sleeping sickness: in vitro and in vivo efficacy of aza analogs of DB289.
AID565604Antimicrobial activity against Trypanosoma evansi STIB 806K infected in NMRI mouse assessed as complete cure from microbial infection at 0.25 mg/kg, ip administered 3 to 6 days after infection for 4 consecutive days2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
In vivo investigations of selected diamidine compounds against Trypanosoma evansi using a mouse model.
AID322577Antiprotozoal activity against Plasmodium falciparum K1 2008Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2
Synthesis and antiprotozoal activity of novel bis-benzamidino imidazo[1,2-a]pyridines and 5,6,7,8-tetrahydro-imidazo[1,2-a]pyridines.
AID340907Drug level in Trypanosoma brucei brucei S427 at 7.5 uM after 24 hrs2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Diphenyl furans and aza analogs: effects of structural modification on in vitro activity, DNA binding, and accumulation and distribution in trypanosomes.
AID454675Cytotoxicity against rat L6 cells2009Bioorganic & medicinal chemistry, Sep-15, Volume: 17, Issue:18
Synthesis and activity of azaterphenyl diamidines against Trypanosoma brucei rhodesiense and Plasmodium falciparum.
AID340904Binding affinity to poly(dA).poly(dT) assessed as increase in melting temperature2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Diphenyl furans and aza analogs: effects of structural modification on in vitro activity, DNA binding, and accumulation and distribution in trypanosomes.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's6 (75.00)29.6817
2010's2 (25.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.26

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.26 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.26 (4.65)
Search Engine Demand Index31.18 (26.88)
Search Engine Supply Index3.82 (0.95)

This Compound (22.26)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
diminazene
Diminazene: An effective trypanocidal agent.. diminazene : A triazene derivative that is triazene in which each of the terminal nitrogens is substituted by a 4-carbamimidoylphenyl group.		2.0510carboxamidine;
triazene derivative		antiparasitic agent;
trypanocidal drug
pentamidine
Pentamidine: Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of PNEUMOCYSTIS pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects.. pentamidine : A diether consisting of pentane-1,5-diol in which both hydroxyl hydrogens have been replaced by 4-amidinophenyl groups. A trypanocidal drug that is used for treatment of cutaneous leishmaniasis and Chagas disease.		3.1450aromatic ether;
carboxamidine;
diether		anti-inflammatory agent;
antifungal agent;
calmodulin antagonist;
chemokine receptor 5 antagonist;
EC 2.3.1.48 (histone acetyltransferase) inhibitor;
NMDA receptor antagonist;
S100 calcium-binding protein B inhibitor;
trypanocidal drug;
xenobiotic
suramin
Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.. suramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years.		2.0510naphthalenesulfonic acid;
phenylureas;
secondary carboxamide		angiogenesis inhibitor;
antinematodal drug;
antineoplastic agent;
apoptosis inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
GABA antagonist;
GABA-gated chloride channel antagonist;
purinergic receptor P2 antagonist;
ryanodine receptor agonist;
trypanocidal drug
melarsoprol
Melarsoprol: Arsenical used in trypanosomiases. It may cause fatal encephalopathy and other undesirable side effects.		2.0510triazines
melarsomine
melarsomine: structure given in first source		2.0510
furamidine
furamidine: RN given refers to parent cpd; WR 199385 refers to di-HCl; pafuramidine is a prodrug of this		3.5580
db 244
[no description available]		2.0310
furimidazoline
furimidazoline: structure in first source		2.0310
pafuramidine
pafuramidine: a prodrug of furamidine		3.1450
ConditionIndicatedRelationship StrengthStudiesTrials
African Sleeping Sickness
[description not available]		03.1450
Trypanosomiasis, African
A disease endemic among people and animals in Central Africa. It is caused by various species of trypanosomes, particularly T. gambiense and T. rhodesiense. Its second host is the TSETSE FLY. Involvement of the central nervous system produces African sleeping sickness. Nagana is a rapidly fatal trypanosomiasis of horses and other animals.		03.1450
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.9740
Plasmodium falciparum Malaria
[description not available]		02.4620
Malaria, Falciparum
Malaria caused by PLASMODIUM FALCIPARUM. This is the severest form of malaria and is associated with the highest levels of parasites in the blood. This disease is characterized by irregularly recurring febrile paroxysms that in extreme cases occur with acute cerebral, renal, or gastrointestinal manifestations.		02.4620
Trypanosomiasis
Infection with protozoa of the genus TRYPANOSOMA.		02.0510